Calendario›TVRD›TTI-101

TTI-101

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Ensayo de Tvardi Therapeutics, Inc. en Breast Cancer · Head and Neck Squamous Cell Carcinoma · Non Small Cell Lung Cancer · Hepatocellular Cancer · Colorectal Cancer · Gastric Adenocarcinoma · Melanoma · Advanced Cancer (del registro, en inglés).

Más ensayos de: Cáncer de mama · Carcinoma escamoso de cabeza y cuello · Cáncer de pulmón no microcítico · Cáncer colorrectal · Adenocarcinoma gástrico · Melanoma · Cáncer avanzado.

Fase

Fase 1

Estado

Completado

Participantes

64

previstos

Centros

2

Fin del objetivo primario

jun 2024

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en nov 2017.

Qué mide

Maximum Tolerated Dose of TTI-101 (del registro, en inglés) (28 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroMany patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3's importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.

Más ensayos de TVRD

Todos los de TVRD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03195699), actualizada en mar 2025.